Aimei Health Technology (
NASDAQ:AFJK -
Get Free Report) posted its earnings results on Wednesday. The company reported $0.07 EPS for the quarter,
Zacks reports.
Aimei Health Technology Price Performance
Shares of Aimei Health Technology stock remained flat at $11.17 during mid-day trading on Wednesday. 200 shares of the company's stock traded hands, compared to its average volume of 1,659. Aimei Health Technology has a 1 year low of $10.24 and a 1 year high of $11.30. The firm's 50 day moving average is $11.16 and its 200-day moving average is $11.04.
About Aimei Health Technology
(
Get Free Report)
Aimei Health Technology Co, Ltd does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. It intends to acquires businesses in the biopharmaceutical, medical technology/device industries or diagnostic, and other services sectors.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aimei Health Technology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aimei Health Technology wasn't on the list.
While Aimei Health Technology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.